According to preliminary research, the immunizer has been shown to be more effective than previous coronavirus infections; result needs to be peer reviewed
A preliminary study by researchers at the University of KwaZulu-Natal indicates that the vaccine developed by the North American company Novavax has 51% effectiveness against the variant of Covid-19 South Africa, the B.1.351. The safety and efficacy study of phase 2 of the immunizer was carried out with about 4 thousand volunteers South Africans, where the mutation is more common. The essay was published as a pre-print on the medRxiv scientific portal and the result needs to be reviewed by peers.
Approximately 30% of participants had already been infected with the coronavirus when they signed up. Those who received placebo injections were just as likely to get Covid-19 as those who were vaccinated, according to the researchers. “Among 94% of participants without HIV, the overall effectiveness of the vaccine was 60.1%. The study was not designed to detect efficacy in the small population of people living with HIV, ”they said. Among volunteers who were infected with variant B.1.351, the protective efficacy after immunization was 51% among participants with HIV negative.
In addition, according to the researchers, the Novavax vaccine was effective in preventing coronavirus variant B.1.351. Evidence of previous infection with the original Sars-CoV-2 did not provide protection against the mutation. “This discovery has significant public health implications for creating pandemic control strategies, developing vaccines and implementing efforts,” wrote the team.
The latest study on the Novavax demonstrated that the vaccine is 89% effective against coronavirus in studies conducted in the UK. Phase 3, the last one before the immunization was approved, involved 15 thousand volunteers between 18 and 84 years of age – 27% of the volunteers were over 65 years old. The country, which already has three vaccines approved for use, now expects rapid approval from Novavax. The UK bought 60 million doses of the vaccine, which will also be produced locally, at a factory in the Middlesbrough region.